Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jean Nezivar"'
Autor:
Satoshi Kashiwagi, Jianping Yuan, Benjamin Forbes, Mathew L Hibert, Eugene L Q Lee, Laura Whicher, Calum Goudie, Yuan Yang, Tao Chen, Beth Edelblute, Brian Collette, Laurel Edington, James Trussler, Jean Nezivar, Pierre Leblanc, Roderick Bronson, Kosuke Tsukada, Makoto Suematsu, Jeffrey Dover, Timothy Brauns, Jeffrey Gelfand, Mark C Poznansky
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e82899 (2013)
Safe and effective immunologic adjuvants are often essential for vaccines. However, the choice of adjuvant for licensed vaccines is limited, especially for those that are administered intradermally. We show that non-tissue damaging, near-infrared (NI
Externí odkaz:
https://doaj.org/article/b0b16a47fa6a41578fd3cab79619b31b
Autor:
Jeffrey A. Gelfand, Korochkina Svetlana E, Mai Nguyen, Paramjit Uppal, Mark C. Poznansky, Nadiah Hashim Arrifin, Elda Righi, Xiaoyun Tong, Gilberte Jean-Mary, Sandra Orsulic, Tao Chen, Nathalie Scholler, Yuan Yang, Timothy Brauns, Satoshi Kashiwagi, Jean Nezivar, Glenn Dranoff, Huabiao Chen, Ben Forbes, Patrick Reeves, Roderick T. Bronson, Pierre Leblanc, Jianping Yuan
Publikováno v:
Journal of Hematology & Oncology
Journal of hematology & oncology, vol 7, iss 1
Journal of hematology & oncology, vol 7, iss 1
Background Although dendritic cell (DC) vaccines are considered to be promising treatments for advanced cancer, their production and administration is costly and labor-intensive. We developed a novel immunotherapeutic agent that links a single-chain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::161dfa0d3e068c0f66d10fd5ff10b670
http://hdl.handle.net/11562/1065315
http://hdl.handle.net/11562/1065315
Autor:
Brian Collette, Makoto Suematsu, Jeffrey S. Dover, Laurel Edington, Eugene L. Q. Lee, Jeffrey A. Gelfand, Jianping Yuan, Laura Whicher, Mathew L. Hibert, Roderick T. Bronson, Jean Nezivar, Pierre Leblanc, Kosuke Tsukada, Calum Goudie, James T. Trussler, Yuan Yang, Timothy Brauns, Beth Edelblute, Tao Chen, Benjamin Forbes, Satoshi Kashiwagi, Mark C. Poznansky
Publikováno v:
PLoS ONE, Vol 8, Iss 12, p e82899 (2013)
PLoS ONE
PLoS ONE
Safe and effective immunologic adjuvants are often essential for vaccines. However, the choice of adjuvant for licensed vaccines is limited, especially for those that are administered intradermally. We show that non-tissue damaging, near-infrared (NI
Autor:
Marek Ancukiewicz, Michael Santosuosso, Rakesh K. Jain, Fabrizio Vianello, Jianping Yuan, Dai Fukumura, Mark C. Poznansky, Walid S. Kamoun, Pierre Leblanc, Peigen Huang, Margaret R. Martin, Lance L. Munn, Elda Righi, Jean Nezivar, John D. Martin, Dan G. Duda, Yuhui Huang
The recent approval of a prostate cancer vaccine has renewed hope for anticancer immunotherapies. However, the immunosuppressive tumor microenvironment may limit the effectiveness of current immunotherapies. Antiangiogenic agents have the potential t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::289b12adf99489de904522dd7deaee0d
https://europepmc.org/articles/PMC3491458/
https://europepmc.org/articles/PMC3491458/
Autor:
Mark C. Poznansky, Jean Nezivar, Yuan Yang, Satoshi Kashiwagi, Timothy Brauns, N. Hashim Arrifin, G. Jean-Mary, Jason X.-J. Yuan, Pierre Leblanc, M. Nguyen
Publikováno v:
Gynecologic Oncology. 133:90
Autor:
Elda Righi, Michael Santosuosso, Mark C. Poznansky, Jeffrey A. Gelfand, Satoshi Kashiwagi, Pierre Leblanc, Sandra Orsulic, Jianping Yuan, Jean Nezivar, Glenn Dranoff, Nathalie Scholler, Korochkina Svetlana E
Publikováno v:
Cancer Research. 72:1578-1578
Background and Purpose: There is a clear logic to adjuvant immunotherapy to enhance conventional treatment of ovarian cancer. Mesothelin (MSLN) is a surface glycoprotein expressed at high levels by ovarian cancers and is already a clinical target for